Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report

Hepatocellular carcinoma is a malignancy with an increasing incidence worldwide and is one of the most serious cancers in adults. We encountered a case of initially unresectable massive hepatocellular carcinoma in which conversion to curative resection and pathological complete response were achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Taisuke, Fujikawa, Takahisa, Uemoto, Yusuke, Aibe, Yuki, Hasegawa, Suguru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
General Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575677/
https://www.ncbi.nlm.nih.gov/pubmed/37842353
http://dx.doi.org/10.7759/cureus.45176
_version_ 1785120964132995072
author Matsuoka, Taisuke
Fujikawa, Takahisa
Uemoto, Yusuke
Aibe, Yuki
Hasegawa, Suguru
author_facet Matsuoka, Taisuke
Fujikawa, Takahisa
Uemoto, Yusuke
Aibe, Yuki
Hasegawa, Suguru
author_sort Matsuoka, Taisuke
collection PubMed
description Hepatocellular carcinoma is a malignancy with an increasing incidence worldwide and is one of the most serious cancers in adults. We encountered a case of initially unresectable massive hepatocellular carcinoma in which conversion to curative resection and pathological complete response were achieved after atezolizumab plus bevacizumab therapy. Atezolizumab plus bevacizumab combination chemotherapy may be one of the most promising options for unresectable hepatocellular carcinoma.
format Online
Article
Text
id pubmed-10575677
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105756772023-10-14 Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report Matsuoka, Taisuke Fujikawa, Takahisa Uemoto, Yusuke Aibe, Yuki Hasegawa, Suguru Cureus General Surgery Hepatocellular carcinoma is a malignancy with an increasing incidence worldwide and is one of the most serious cancers in adults. We encountered a case of initially unresectable massive hepatocellular carcinoma in which conversion to curative resection and pathological complete response were achieved after atezolizumab plus bevacizumab therapy. Atezolizumab plus bevacizumab combination chemotherapy may be one of the most promising options for unresectable hepatocellular carcinoma. Cureus 2023-09-13 /pmc/articles/PMC10575677/ /pubmed/37842353 http://dx.doi.org/10.7759/cureus.45176 Text en Copyright © 2023, Matsuoka et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle General Surgery
Matsuoka, Taisuke
Fujikawa, Takahisa
Uemoto, Yusuke
Aibe, Yuki
Hasegawa, Suguru
Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
title Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
title_full Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
title_fullStr Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
title_full_unstemmed Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
title_short Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
title_sort conversion to curative resection and pathological complete response following targeted therapies with atezolizumab and bevacizumab for initially unresectable hepatocellular carcinoma: a case report
topic General Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575677/
https://www.ncbi.nlm.nih.gov/pubmed/37842353
http://dx.doi.org/10.7759/cureus.45176
work_keys_str_mv AT matsuokataisuke conversiontocurativeresectionandpathologicalcompleteresponsefollowingtargetedtherapieswithatezolizumabandbevacizumabforinitiallyunresectablehepatocellularcarcinomaacasereport
AT fujikawatakahisa conversiontocurativeresectionandpathologicalcompleteresponsefollowingtargetedtherapieswithatezolizumabandbevacizumabforinitiallyunresectablehepatocellularcarcinomaacasereport
AT uemotoyusuke conversiontocurativeresectionandpathologicalcompleteresponsefollowingtargetedtherapieswithatezolizumabandbevacizumabforinitiallyunresectablehepatocellularcarcinomaacasereport
AT aibeyuki conversiontocurativeresectionandpathologicalcompleteresponsefollowingtargetedtherapieswithatezolizumabandbevacizumabforinitiallyunresectablehepatocellularcarcinomaacasereport
AT hasegawasuguru conversiontocurativeresectionandpathologicalcompleteresponsefollowingtargetedtherapieswithatezolizumabandbevacizumabforinitiallyunresectablehepatocellularcarcinomaacasereport

Ejemplares similares